GlassScriptPhysician profile
Mallory Cardenas
NPI 1518687953
$2,260.43
in general payments reported to CMS, 2019-2025
20 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $960 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.66 | 2024-2025 | |
| Gilead Sciences, INC. | $357.43 | 2023-2025 | Epclusa |
| Alkermes, INC. | $353.34 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $255.30 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $124.36 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.12 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $107.01 | 2023-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $94.28 | 2024-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $73.01 | 2025 | Qelbree |
| Indivior INC. | $49.05 | 2024-2025 | Sublocade, Perseris |
| Lundbeck LLC | $48.38 | 2024-2025 | Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $40.16 | 2024 | Austedo Xr |
| Exact Sciences Corporation | $36.26 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $27.18 | 2025 | Cobenfy |
| Astellas Pharma US INC | $23.41 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $22.89 | 2025 | Erzofri Extended-Release |
| Axsome Therapeutics, INC. | $17.03 | 2023 | Auvelity |
| Dexcom, INC. | $16.70 | 2025 | Dexcom G6 Transmitter |
| Owp Pharmaceuticals, INC. | $15.54 | 2024 | Subvenite |
| Corium, LLC | $15.32 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Cardenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.